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Purpose: Oxidative stress plays an important role in the patho-
genesis of several neurodegenerative diseases including glaucoma.
Astrocytes are supposed to play a role in glaucoma pathogenesis.
This study investigates the antiapoptotic and cytoprotective effects
of idebenone on optic nerve head astrocytes (ONHA) under oxi-
dative stress.
Methods: ONHA were treated with 1 to 150mM idebenone. Cell
viability (MTT assay and live-dead assay), induction of intra-
cellular reactive oxygen species, senescence-associated b-gal-
actosidase activity were investigated. In addition, apoptosis
(detection of histone-associated DNA fragmentation), and
expression of BAX and Bcl-2, and their mRNA were determined
after 48 hours and after hydrogen peroxide (H2O2) treatment.
Results: Idebenone concentrations from 1 to 50 mM showed no
effects on ONHA viability. Pretreatment with 10mM idebenone led
to an increase in viability of ONHA after H2O2 treatment. In
addition, idebenone pretreatment significantly attenuated the
increase of histone-associated DNA fragmentation, induction of
senescence-associated b-galactosidase, and intracellular reactive
oxygen species after treatment with H2O2. When ONHA cells were
treated with idebenone and H2O2, real-time polymerase chain
reaction and Western blot analysis yielded an increased expression
of Bcl-2 and a decrease of BAX compared with those cells that were
treated with H2O2 only.
Conclusions: Idebenone reduced senescence, oxidative stress, and
apoptotic cell death in cultured ONHA in vitro. Our results suggest
that idebenone may help to protect ONHA in vivo, and therefore
might be helpful in preventing the progression of glaucomatous
degeneration.
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Glaucoma is a distinctive group of progressive neuro-degenerative diseases affecting the optic nerve. It is
characterized by accelerated death of retinal ganglion cells
(RGCs) and circumjacent glial cells. Consequently, with the
progression of glaucoma, an irretrievable loss of visual field
and eventual blindness occurs.1 Currently, an estimated 60
million people have glaucoma, and it is the second leading
cause of blindness worldwide.1 The number of patients
affected by glaucoma is estimated to increase to 80 million
by 2020.1
To date, lowering intraocular pressure (IOP) is the
only treatment proven to decrease the development2 and
progression3 of glaucomatous optic nerve damage. Beside
IOP, there are several risk factors for glaucoma progression
including age, central corneal thickness, exfoliation, or
lower ocular systolic perfusion pressure.4,5 Lowering IOP
alone does not halt the progression of the disease in all
patients, and additional therapeutic approaches for pro-
tecting the optic nerve are sought.4,5
Looking at the cellular level of glaucoma’s patho-
genesis, there is increasing evidence that apoptosis is an
important mechanism of neuronal cell (RGCs) death, as
well as of supportive glial cells in glaucomatous neuro-
degeneration. Apoptotic cell death has been observed in
both animal glaucoma models and human eyes with
glaucoma.6–9
In the eye, astrocytes are present both in the inner
retina as well as in the unmyelinated optic nerve head
astrocytes (ONHA) and act as neuronal supportive cells by
regulating ionic balance, metabolic supply, and structural
support.10–12 Ocular astrocytes are thought to contribute to
both homeostatic functions of the RGCs and optic nerve,
as well as directly contributing to the pathophysiology
resulting in damage to both ganglion cells and optic
nerve.10–13
Astrocytes, and glial cells in general, are the interface
between neurons and vasculature and thus are strategic key
regulators of the nutrition and metabolism of RGCs and
the optic nerve.14 In glaucoma the communication between
RGCs and these supportive glial cells is strongly dis-
turbed.14,15 Glaucomatous neuropathology leads to a
change of glial cell morphology and protein expression, a
process referred to as glial activation (or reactive gliosis).16
Prelaminar ONHAs round up and migrate, abandoning
their columnar organization. It was shown previously that
the inhibition of reactive gliosis can attenuate the death of
RGCs17; thus, providing proof of concept for pursuing
other novel inhibitors of reactive gliosis as potential new
treatment options for patients with glaucoma.
Oxidative stress is a prominent feature of aging and
has been implicated as a relevant factor in the development
of many diseases, including glaucoma.18–23 Moreover, oxi-
dative stress can lead to apoptosis of both, RGCs them-
selves and supportive glial cells like ONHAs. The processes
that lead to the development of oxidative stress may also
contribute to neurodegeneration in glaucoma.24–26
Idebenone (2,3-dimethoxy-5-methyl-6-[10-hydroxydecyl]-
1,4-benzoquinone) is a benzoquinone derivative that is
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structurally related to ubiquinone (coenzyme Q10), a compo-
nent of the respiratory chain.27 Although the precise mecha-
nism of action of the drug is unknown, preclinical studies have
suggested that idebenone may exert cytoprotective properties
by acting as a scavenger of free radicals.27 Beneficial effects of
idebenone have been demonstrated in the treatment of several
neurodegenerative diseases in which glial tissue is involved in
the pathogenesis, including the Leber hereditary optic neuro-
pathy.28–33 Besides the antioxidant properties of idebenone,
effects of the substance on expression of antiapoptotic proteins
also have been described.34,35
Oxidative stress is a pathological condition in which
the rate of reactive oxygen species (ROS) production
exceeds the body’s antioxidative capacity. In various neu-
rodegenerative diseases, localization of tissue markers of
oxidative stress to lesion areas has led to suggestions that
oxidative injury contributes to the disease process. Astro-
cytes seem to be highly susceptible to oxidative stress, and
astrocyte dysfunction is closely related to glaucomatous
optic nerve damage.14,15,25,36
This study investigates the effects of idebenone on
oxidative stress, cellular senescence, and apoptosis of pri-
mary human ONHA as a possible treatment option for
diagnosed glaucoma patients.
METHODS
Idebenone was generously provided by Santhera
Pharmaceuticals (Liestal, Switzerland). The compound was
dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St
Louis, MO) and diluted with DMSO and the cell culture
medium to the desired concentration with a final DMSO
concentration of 0.1% (v/v) for in vitro studies. DMSO was
added to cultures at 0.1% (v/v) as a solvent control.
Ethics
The methods of securing human tissue were humane,
included proper consent and approval, complied with the
Declaration of Helsinki, and were approved by the local
ethics committee.
Primary Human ONHA Culture
Primary cell cultures of human lamina cribrosa
astrocytes were obtained from the eye bank of the Ludwig
Maximilian University (Munich, Germany). Monolayer
cultures were established from eyes of 4 human donors (29,
41, 52, and 74 y old, obtained 3 to 10 h postmortem)
without any history of eye diseases. The eyes were prepared
and grown as previously described.10–12 A 1:1 mixture of
Dulbecco-modified Eagle medium (DMEM) and Ham F-12
medium was used for cell culture and passages 2 to 5 were
used for our experiments.
Cell Culture Treatment
For tetrazolium dye-reduction assay (MTT; 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)
and propidium iodide (PI)/Hoechst 33342 staining, ONHA
were seeded in 6-well tissue culture plates and exposed to
various idebenone concentrations (1, 5, 7.5, 10, 15, 20, 40,
50, 75, 100, and 150mM). To investigate the effects of ide-
benone on ONHA regarding RNA and protein expression,
an idebenone concentration of 10mM was chosen.
For all other cell culture experiments, ONHA were
seeded in the tissue culture plates and cultured upon con-
fluence. For the last 48 hours, 10mM idebenone was added
to the cell culture medium. Then ONHA were kept for 24
hours in serum-free conditions: after the cells were washed
with phosphate-buffered saline (PBS), they were incubated
for another 24 hours with idebenone (10 mM) dissolved in
serum-free DMEM/F12 medium.
To test the effects of idebenone under conditions of
oxidative stress, ONHA were exposed to hydrogen peroxide
(H2O2). In unpublished prework of our laboratory several
concentrations of H2O2 and times of treatment were tested
and the concentration of 600 mM H2O2 and a 4-hour
treatment was chosen in order to produce an adequate
degree of cell injury in untreated ONHA. To investigate
idebenones effect on H2O2-induced cellular damage, cells
were treated as described above, but 600mM H2O2 was
added for the last 4 hours. Then the serum-free medium
containing H2O2 and idebenone was removed by carefully
rinsing the cells with serum-free medium 3 times. After
another 24 hours of incubation with serum-free medium,
MTT assay, PI, and Hoechst 33342 staining, quantitative
detection of histone-associated DNA fragments in mono-
nucleosomes and oligonucleosomes, CM-H2DCFDA
staining, and senescence-associated b-galactosidase (SA b-
Gal) staining were investigated. In addition, real-time pol-
ymerase chain reaction (RT-PCR) analysis and Western
blotting was performed.
MTT Assay
The MTT assay is a well-established test for measuring
metabolic activity of cells, and it can occasionally be used
as indirect measure of cell viability. To determine metabolic
activity of ONHA, MTT assay was performed as described
in the literature by Mosmann, with some mod-
ifications.37–39 The medium was removed, cells were washed
with PBS, and 1000 mL/well MTT solution (1.5mL MTT
stock, 2mg/mL in PBS, plus 28.5mL DMEM) was added.
ONHA were incubated at 371C for 1 hour. The formazan
crystals that formed were dissolved by the addition of
DMSO (1000mL/well). Absorption was measured by a
scanning multiwell spectrophotometer (Molecular Probes,
Garching, Germany) at 550 nm. Results are expressed as
the mean percentage of control proliferation. Experiments
were performed in triplicate and repeated 3 times.
Untreated ONHA of the same passage served as the con-
trol. Values of each sample were normalized to a “blank”
containing DMSO only.
PI and Hoechst 33342 Staining
Confluent ONHA were prepared and treated as
described above. Cell viability was quantified by PI (Sigma-
Aldrich) and Hoechst 33342 (Intergen, Purchase, NY)
double staining. Confluent cultures of ONHA growing on
coverslips were exposed to the same concentrations of
idebenone as in the MTT assay. Then, cells were washed in
PBS and incubated with 2.0 mg/mL PI and 1.0mg/mL
Hoechst 33342 resolved in PBS for 20 minutes at 371C.
Subsequently, stains were removed, cells were washed with
PBS, and then analyzed with an epifluorescence microscope
(Aristoplan; Leitz, Wetzlar, Germany). The labeled nuclei
were then counted in fluorescence photomicrographs, and
the percentage of PI-labeled nuclei was counted in 3 to 5
documented representative fields per well. The data are
based on counts in 3 experiments performed in duplicate
wells, with untreated ONHA of the same passage serving as
the control.
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Detection of Histone-associated DNA Fragments
in Mononucleosomes and Oligonucleosomes
Apoptosis is characterized by membrane blebbing,
condensation of cytoplasm, and the activation of endoge-
nous endonucleases. This leads to internucleosomal cleav-
age of DNA and the generation of mononucleosomes and
oligonucleosomes that are tightly complexed with histones.
To quantify apoptosis in ONHA, detection of histone-
associated DNA fragments in mononucleosomes and oli-
gonucleosomes was performed by enzyme-linked immune
sorbent assay (ELISA). ONHA were treated with idebe-
none (10 mM) as described above. Cells were then collected
from culture plates and subjected to a cell death detection
ELISA (Roche Applied Science, Indianapolis, IN) accord-
ing to the manufacturer’s recommendations.
Detection of SA b-Gal Activity
The proportion of ONHA positive for SA b-Gal
activity was determined as described by Dimri et al.40
Briefly, treated ONHA were washed twice with PBS and
fixed with 2% formaldehyde and 0.2% glutaraldehyde in
PBS (pH 6.0) at room temperature for 4 minutes. The cells
were then washed twice with PBS and incubated for 8 hours
at 371C with freshly prepared SA b-Gal staining solution
[1mg/mL 5-bromo-4-chloro-3-indoyl-b-D-galactopyrano-
side, 40mM citric acid-sodium phosphate solution (pH
6.0), 5mM potassium ferrocyanide, 5mM potassium ferri-
cyanide, 150mMNaCl, and 2mMMgCl2 diluted in PBS] in
darkness. Subsequently, SA b-Gal staining solution was
removed, cells were washed with PBS and cells were
then examined for the development of blue color and
photographed at low magnification (200) using a light
microscope. The results are expressed as mean average
percentage±SD of 12 experiments using ONHA cultures
from 4 donors.
Detection of Intracellular ROS
Intracellular ROS production was detected by the
method described by Nishikawa and colleagues39,41,42
ONHA cultured in presence of 10 mM idebenone were
treated with 600mM H2O2 as described above. Then the
cells were supplemented with 5-(and-6)-chloromethyl-20,70-
dichlorodihydro-fluorescein diacetate acetyl ester (CM-
H2DCFDA; Molecular Probes, Eugene, OR) dissolved in
Krebs-Ringer bicarbonate buffer (135mM NaCl, 3.6mM
KCl, 10mM HEPES, 5mM NaHCO3, 0.5mM NaH2PO4,
0.5mM MgCl2, pH 7.4) to a final concentration of 10mM
CM-H2DCFDA for 30 minutes, incubated with DMEM/
F12 medium for 2 hours. Subsequently, CM-H2DCFDA
staining solution was removed, cells were washed with PBS
and analyzed under an epifluorescence microscope (Aris-
toplan; Leitz).
RNA Isolation and RT-PCR
RNA isolation by using the guanidium thiocyanate-
phenol-chloroform extraction method and RT-PCR using
the LightCycler System (Roche Diagnostics, Mannheim,
Germany) was performed as described previously.11,43
Quantitation of Bcl-2 and BAX mRNA was performed
with specific primers (Table 1). Primers and probes were
selected by the ProbeFinder version 2.04 software. All
primers and probes were designed to cross intron-exon
boundaries in order to avoid amplification of genomic
DNA. All PCR products were sequenced to ensure product
validity. To normalize for differences in the amount of total
RNA added to each reaction, 18S rRNA was simulta-
neously processed in the same sample as an internal control.
The levels of Bcl-2 and BAX mRNA were determined as
the relative ratio, which was calculated by dividing the level
of Bcl-2 or BAX mRNA by the level of the 18S rRNA
housekeeping gene in the same samples. Ratios are
expressed in a decimal format. All experiments were per-
formed at least in triplicate and repeated 3 times.
Protein Extraction and Western Blot Analysis
ONHA grown on 35-mm tissue culture plates were
washed twice with ice-cold PBS, collected, and lysed in
RIPA cell lysis buffer. After centrifugation for 30 minutes
at 19,000g in a microfuge (5810R; Eppendorf, Hamburg,
Germany) in the cold, the supernatant was transferred to
fresh tubes and stored at –701C for future use. The protein
content was measured by the bicinchoninic acid protein
assay (Pierce, Rockford, IL). Denatured proteins (1.2mg)
were separated by electrophoresis under reducing con-
ditions using a 5% sodium dodecyl sulfate-polyacrylamide
stacking gel and a 12% sodium dodecyl sulfate-poly-
acrylamide separating gel, transferred with semidry blotting
onto a polyvinyl difluoride membrane (Roche), and probed
with a mouse anti-Bcl-2-antibody or a mouse anti-BAX-
antibody as described previously.39,43 Chemiluminescence
was detected with an imager (LAS-1000; RayTest) and
generated light units as described previously.38,43 Exposure
times ranged from 1 to 10 minutes. Quantification was
performed using AIDA software (RayTest). All experi-
ments were performed at least in triplicate in ONHA cul-
tures from 3 donors. An even protein load in each lane was
confirmed by staining of the polyvinyl difluoride mem-
branes with Coomassie brilliant blue after the blotting and
detection procedure.
Statistical Analysis
Data were analyzed using SPSS 13.0 for Windows
(SPSS Inc., Chicago, IL). Statistical comparisons among
the different concentrations of idebenone (each repeated 3
times and measured in triplicate) was performed with the
Mann-Whitney test. For the MTT assay quantitative
results are presented as mean (SD) units of absorbance. Ten
TABLE 1. Primers Used for RT-PCR
Target Length Position AT (1C) % GC Sequence
Bcl-2 19 3465-3483 60 58 agaggtcacgggggctaat
20 3505-3524 60 50 ccaggtaacaaaaccccaca
BAX 18 526-543 59 61 caagaccagggtggttgg
18 592-609 59 56 cactcccgccacaaagat
RT-PCR indicates real-time polymerase chain reaction.
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individual samples per group were measured in triplicate
and comparisons were performed using the Mann-Whitney
test. For RT-PCR, the results are presented as mean ratios
(SD) of the investigated mRNA and 18S rRNA. Again,
Mann-Whitney testing was applied, and all experiments
were performed in triplicate and repeated 3 times. For all
statistical tests, P<0.05 was considered significant.
RESULTS
MTT Assay, and PI/Hoechst 33342 Staining
We analyzed the dose-dependent toxic effects of ide-
benone at concentrations of 1, 5, 7.5, 10, 15, 20, 40, 50, 75,
100, and 150 mM by MTT assay and PI/Hoechst 33342
staining.
MTT Assay
Idebenone showed no significant effects on metabolic
activity of ONHA cell cultures (48-h exposure) at concen-
trations between 1 and 50 mM (Fig. 1). No significant
decrease was detected in cellular viability of ONHA com-
pared with the controls at concentrations up to 50mM.
Idebenone concentrations of 75 mM and higher for primary
ONHA led to a dose-dependent reduction of metabolic
activity of cells. When ONHA cells were also treated with
H2O2, those cells pretreated with idebenone concentrations
of 7.5 to 20 mM showed a significant increase in metabolic
activity, with a peak at 10 mM (P<0.001) compared with
the control (Fig. 1).
PI and Hoechst 33342 Staining
The viability of primary ONHA was tested by labeling
the nuclei of nonviable cells with PI 48 hours after treat-
ment of the cells with idebenone and H2O2. Idebenone
concentrations of 1 to 100mM did not show any significant
effect on ONHA cell viability (Fig. 2). When primary
ONHA were treated with an idebenone concentration of
10 mM for 48 hours and additionally treated with 600mM
H2O2 for 4 hours, idebenone concentrations of 10 mM led to
a significant increase in viability compared with the control,
which was treated with 600mM H2O2 only (Fig. 2). By
contrast, idebenone concentrations of 75mM and higher
induced a marked reduction in the viability of ONHA cells
in a dose-dependent manner after exposure to 600mMH2O2
for 4 hours.
SA b-Gal Activity
Idebenone (10 mM) had no significant effect on SA b-
Gal activity in ONHA. In contrast, addition of 600mM
H2O2, significantly increased SA b-Gal activity. A sig-
nificantly reduced SA b-Gal activity was noted when cells
were pretreated with 10 mM idebenone and then exposed to
600 mM H2O2 (Fig. 3A, upper row, and Fig. 3B).
Intracellular ROS
In untreated ONHA only a faint CM-H2DCFDA
staining of ONHA was detected. After treatment of ONHA
with 10 mM idebenone no significant increase in CM-
H2DCFDA staining could be detected, whereas after
treatment with 600 mM H2O2 CM-H2DCFDA staining was
markedly increased (Fig. 3A, lower row). When ONHA
were pretreated with 10 mM idebenone and then treated
with 600mM H2O2, CM-H2DCFDA staining was noted,
but it was markedly less pronounced compared with cells
that were treated with 600 mM H2O2 alone (Fig. 3A, lower
row).
Detection of Histone-associated DNA Fragments
in Mononucleosomes and Oligonucleosomes
To investigate the putative effects of idebenone on
H2O2-induced apoptosis in ONHA, detection of histone-
associated DNA fragments in mononucleosomes and oli-
gonucleosomes was conducted using the ELISA method. In
our experimental set-up, exposure to 600mM H2O2 led to a
significant increase of histone-associated DNA fragments in
cultured ONHA. In contrast, when cells were pretreated
with idebenone and then exposed to 600mM H2O2, idebe-
none treatment decreased the amount of histone-associated
DNA fragments significantly, compared with those cells
that were not pretreated with idebenone (Fig. 4).
Expression of Bcl-2 and BAX mRNA in ONHA
BAX and Bcl-2 mRNA expression was detected in
every sample. All detected mRNA levels of BAX and Bcl-2
were normalized to those of 18S rRNA; the values are
expressed as the relative ratio of Bcl-2/18S or BAX/18S.
Treatment with H2O2 led to a significant decrease in Bcl-2
mRNA expression in ONHA, but this decrease of Bcl-2
mRNA expression after exposure to oxidative stress was
significantly reduced when cells were pretreated with ide-
benone (Fig. 5). In contrast, expression of BAX mRNA
was increased in ONHA after H2O2 treatment, and pre-
treatment of ONHA with idebenone significantly reduced
this H2O2-induced increase in BAX (Fig. 5).
Protein Expression of Bcl-2 and BAX in ONHA
After H2O2 exposure, a marked decrease in Bcl-2
expression could be detected compared with those cells that
were not treated with H2O2. This decrease was reduced
when cells were pretreated with 10 mM idebenone (Fig. 6).
In contrast, BAX expression was increased compared with
the control when cells were exposed to oxidative stress
without idebenone pretreatment. Pretreatment with idebe-
none attenuated this H2O2-mediated stimulation of BAX
protein synthesis (Fig. 6).
DISCUSSION
A number of hypotheses have been proposed and
continue to be investigated to explain the mechanisms of
glaucomatous damage. To date, reduction of IOP is the
only method proven to be effective in preventing or
FIGURE 1. The viability of optic nerve head astrocytes (ONHA)
after 48-hour treatment with various concentrations of idebe-
none (black curve, diamonds) and additionally treated with
600 mM hydrogen peroxide (H2O2) (gray curve, squares), meas-
ured by a colorimetric test (MTT). Error bars, SD. *Significant
difference between the 2 curves.
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delaying progression of glaucomatous damage. However,
given that oxidative stress is associated with degeneration
of neuronal tissue in glaucoma, this process may provide
novel targets for developing new treatments.2–14
In this study, exposure of primary human ONHA to
exogenous oxidative stress not only led to an increase of SA
b-Gal, a specific protein marker for cellular aging processes,
but also an increase of intracellular ROS. Increased gen-
eration of ROS in the optic nerve head and retina has been
demonstrated in experimental animal models of glaucoma
and moderate chronic elevated IOP. Besides, an increase of
intracellular ROS is commonly found in glaucomatous
neurodegeneration.25,26,44 ROS are partially reduced,
highly reactive metabolites derived from one-electron
reduction reactions with oxygen and are mainly generated
via the electron transport chain. An increase in ROS
intermediates and oxidative stress is considered to induce
apoptotic cell death and has been implicated in the pro-
gression of aging.45,46
Mitochondria are ubiquitous in all cells and play an
important role in energy (ATP) production through the
oxidative phosphorylation pathway. They are the major site
of ROS production and play a central role in both extrinsic
and intrinsic apoptotic pathways. In chronic glaucoma,
apoptosis can be found even in early stages of the disease.
Further, mitochondrial dysfunction of both neuronal and
glial cells43 seems to play a key role in the predisposition to
neuronal cell death in almost every age-related disorder,
including glaucoma.24,47 In fact, a variety of apoptotic
stimuli can alter mitochondria permeability and potentially
result in functional disorder, including the release of
proapoptotic proteins such as the BAX protein normally
located in the mitochondrial intermembrane space.9,48,49
BAX is one key protein within a major pathway of the
cell death program. It is upregulated by the tumor sup-
pressor protein p53 and is highly associated with apoptotic
cell death.50–52 In contrast, Bcl-2 is a strong inhibitor of
apoptosis and a counterpart of the BAX protein. It is
generally considered to be a custodian of mitochondrial
functional integrity, as it stabilizes the mitochondrial
membrane against the release of cytochrome c. Bcl-2 is able
to interrupt apoptosis through its inhibitory effect on cas-
pase activation.53,54 An imbalance in the ratio of BAX and
Bcl-2 toward an excess of BAX leads to apoptotic cell death
in many cellular systems.50–54 Therefore, an important
result of our study is that oxidative stress not only led to an
FIGURE 2. ONHA were treated for 48 h with various concentrations of idebenone only or with 10 and 100mg/mL of idebenone
(Idebenone 10 and 100) for 48 h and 600mM H2O2 for 4 h as described. After exposure of the cells to idebenone alone or in
combination with oxidative stress, viability was determined by staining all nuclei with Hoechst 33342 and dead cells with propidium
iodide. A, Control: Representative fluorescence photomicrograph of Hoechst 33342–stained, untreated ONHA as the control and
nonviable cells in the corresponding field. Idebenone 10 and 100: Fluorescence photomicrograph of ONHA treated with 10 mM or
100 mM idebenone for 48 h, labeled with Hoechst 33342, and nonviable ONHA treated with 10 mM for 48 h in the same field. H2O2:
Fluorescence photomicrograph of ONHA treated with 600mM H2O2 only and nonviable ONHA treated with 600mM H2O2 only in the
same field. H2O2 + Idebenone 10 + H2O2: Fluorescence photomicrograph of ONHA treated with idebenone concentrations of 10 mM
for 48 h and with 600 mM H2O2, labeled with Hoechst 33342, and nonviable ONHA treated with idebenone concentrations of 10 mM for
48 h and with 600 mM H2O2 in the same field; scale bar: 500 mm. B, statistical evaluation of “A”; *P < 0.001.
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increase in apoptosis and proapoptotic BAX protein, but
also to a significant decrease of the antiapoptotic Bcl-2
protein in primary human ONHA.
Idebenone is a synthetic analogue of ubiquinone, an
essential constituent of the electron transport chain and a
vital cell membrane antioxidant. Its benzoquinone ring can
undergo reversible reduction-oxidation reactions, and sim-
ilar to ubiquinone, can influence the electron balance within
mitochondria.27 Idebenone interacts with the mitochondrial
respiratory chain as an electron carrier from complexes I
and II to complex III, providing support for mitochondrial
function and ATP production.27 In addition, idebenone
acts as an antioxidant, protecting membranes from damage
by inhibiting lipid peroxidation in mitochondria.27 When
compared with a series of structural analogues, idebenone
seems to have an optimal chemical structure for the resto-
ration of mitochondrial function.55
Because of its ability to support mitochondrial energy
production and its antioxidant action, idebenone was ini-
tially evaluated for the treatment of cognitive disorders and
the Alzheimer disease.34,56,57 In addition, the favorable
safety profile of idebenone and its dual mechanism of
action led to the investigation of its use in other neuro-
degenerative diseases with mitochondrial impairment.33,34
FIGURE 3. Detection of senescence-associated b-galactosidase activity is shown in A: Treatment of primary human ONHA with 10 mM
idebenone did not lead to significantly increased number of cells that were developing the typical color (dark grey) for b-galactosidase
activity compared to the untreated control cells. When cells were treated with 600mM H2O2 a significant increase in b-galactosidase
staining could be detected. This increased number of b-galactosidase positive cells after 600 mM H2O2 treatment was significantly
reduced when cells were pre-incubated with 10mM idebenone for 48 h. B, Detection of intracellular ROS (CM-H2DCFDA): In ONHA
treated with 600mM H2O2 without idebenone pretreatment, an increase in intracellular ROS could be detected. This increase was
reduced when ONHA were pretreated with 10mM idebenone. C, statistical evaluation of “A”; *P < 0.001.
FIGURE 4. Inhibitory effect of idebenone on hydrogen peroxide
(H2O2)-induced apoptosis in optic nerve head astrocytes (ONHA).
Histone-associated DNA fragmentation in ONHA as investigated by
an enzyme-linked immune sorbent assay method. Untreated con-
trol (control), ONHA treated with 600mM H2O2 (H2O2), after
treatment with 10mM idebenone (idebenone) only, or after ide-
benone treatment and additional treatment with 600mM H2O2
(idebenone + H2O2). Y-axis: ratio of histone-associated DNA frag-
mentation of each probe normalized to histone-associated DNA
fragmentation of the control. Data are means ± SD.
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In such disease, idebenone has been shown to reduce
markers of oxidative DNA damage, which are also closely
related to aging processes.27,28
In our in vitro study, idebenone effectively reduced
intracellular ROS in primary human ONHAs. Moreover,
under the investigated experimental conditions of oxidative
stress, idebenone treatment reduced the H2O2-induced
decrease in metabolic activity of cells effectively. These
results support the conclusion that idebenone has the
capacity to reduce oxidative stress in ONHAs and poten-
tially increase viability of these cells under conditions of
oxidative stress in glaucomatous eyes. As the support cells
for RGCs, this could potentially and indirectly result in
increased RGC viability because of the intact support
network.
Supporting these findings, another important result of
our experiments is that pretreatment of ONHA with ide-
benone led to a significant reduction of cell death, apop-
tosis, and SA b-Gal after exposure to oxidative stress.
Moreover, the H2O2-induced increase of BAX and decrease
of Bcl-2 were significantly attenuated by idebenone.
The exact mechanisms of idebenone’s action are not
completely understood. We can speculate that the anti-
apoptotic effects of idebenone in our experimental set-up
are, at least in part, derived from its antioxidant properties.
In contrast, idebenone is structurally related to coenzyme
Q10, which is an important component of the mitochon-
drial respiratory chain directly involved in mitochondrial
electron transport.33 Therefore, idebenone likely has a
direct impact on the intrinsic apoptotic pathway.33,34,58
In conclusion, the data of this in vitro study indicate
that the properties of idebenone allow it to potentially
prevent ONHA death and aging due to oxidative damage
in vivo. Idebenone is a safe and well-tolerated drug.
Therefore, idebenone supplementation might be a feasible
and promising way to prevent the progression of glau-
comatous neurodegeneration by sustaining the viability of
ONHA that assist in maintaining the health of RGC.
Further experimental and preclinical studies will be needed
to substantiate our in vitro findings and define the potential
role of idebenone in the context of clinical glaucoma
treatment.
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